Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Calcipotriene and Betamethasone Suspension in Scalp Psoriasis
NCT03122353Phase 1Completed
- Sponsor
- Tolmar
- Start
- Apr 2017
- Primary completion
- Nov 2017
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of calcipotriol and betamethasone dipropionate spray 0.05% in psoriasis (3 arms), sponsored by Tolmar. Primary endpoints: Psoriasis Area Severity Index at Day 28, Physician Global Assessment at Day 28 and 2 more. Started Apr 2017; status: completed.
02
Drugs
calcipotriolbetamethasone dipropionate spray 0.05%
03
Conditions
psoriasis
Beyond the preview
Go deeper on NCT03122353.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03122353.